News: Schering-Plough

01.01.2010 | NCBI PubMed: Development and Validation of a RP-HPLC Method for the Estimation of Netilmicin Sulfate and its Related Substances using Charged Aerosol Detection.

Netilmicin is a semi-synthetic aminoglycoside antibiotic used against a broad spectrum of Gram-negative bacteria. A reversed-phase high-performance liquid chromatographic method has been developed to determine the composition of netilmicin sulfate and to estimate its related (…)

[Read article]

[Source: NCBI PubMed]

09.09.2010 | BioSpace: 160 Jobs to Go at Schering-Plough Corporation (SGP)'s Cork Pharma Plant

Breaking News - Some 160 jobs are to go at the Schering Plough pharmaceutical plant in west Cork, it emerged this afternoon.

[Read article]

[Source: BioSpace]

26.08.2010 | NCBI PubMed: SCH 602539, a Protease-Activated Receptor-1 Antagonist, Inhibits Thrombosis Alone and in Combination With Cangrelor in a Folts Model of Arterial Thrombosis in Cynomolgus Monkeys.

OBJECTIVE: To determine the antithrombotic effects of SCH 602539, an analog of the selective protease-activated receptor (PAR)-1 antagonist vorapaxar (formerly SCH 530348) currently in advanced clinical development, and the P2 years12 ADP receptor antagonist cangrelor, alone (…)

[Read article]

[Source: NCBI PubMed]

07.09.2010 | Marketwire: Cegedim Strategic Data (CSD) Releases Results of International Rep Quality Survey

PARIS-(Marketwire - September 7, 2010) - Cegedim Strategic Data, leading provider of integrated healthcare research, announces the results of its international Rep Quality Survey. As emerging markets remain a focus area for growth for the pharmaceutical industry, CSD conducted (…)

[Read article]

[Source: Marketwire]

03.09.2010 | Business Wire: Gleacher & Company Welcomes Another Addition to Equity Healthcare Team | Business Wire

NEW YORK-(BUSINESS WIRE)-Gleacher & Company Securities, Inc., a broker-dealer subsidiary of Gleacher & Company, Inc. (Nasdaq: GLCH), today announced another addition to its Healthcare Research team with the hiring of Ying Huang. I continue to believe that expanding our equity (…)

[Read article]

[Source: Business Wire]

02.09.2010 | Business Wire: MSD Receives European Approval of its Atypical Antipsychotic Medication SYCREST (asenapine) for the Treatment of Manic Episodes in Bipolar I Disorder | Business Wire

WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)-MSD (MSD is a tradename of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A). announced today that the European Commission has approved the Marketing Authorization Application (MAA) for SYCREST (asenapine) (…)

[Read article]

[Source: Business Wire]

01.09.2010 | Business Wire: BRINAVESS ¢ (vernakalant) for Infusion Approved in the European Union for Rapid Conversion of Recent Onset Atrial Fibrillation | Business Wire

WHITEHOUSE STATION, N.J. & VANCOUVER, British Columbia-(BUSINESS WIRE)-Merck (known as MSD outside the United States and Canada) (NYSE:MRK) and Cardiome Pharma Corp. (NASDAQ: CRME/ TSX: COM) today announced that the intravenous (IV) formulation of BRINAVESS ¢ (vernakalant) (…)

[Read article]

[Source: Business Wire]

01.09.2010 | Business Wire: BRINAVESS ¢ (vernakalant) for Infusion Approved in the European Union for Rapid Conversion of Recent Onset Atrial Fibrillation | Business Wire

WHITEHOUSE STATION, N.J. U.S.A. & VANCOUVER, British Columbia-(BUSINESS WIRE)-MSD (known in the US and Canada as Merck) (NYSE:MRK) and Cardiome Pharma Corp. (NASDAQ: CRME/ TSX: COM) today announced that the intravenous (IV) formulation of BRINAVESS ¢ (vernakalant) has been (…)

[Read article]

[Source: Business Wire]

27.08.2010 | Bionity.com: Regenicin Appoints Amgen Co-founder Dr. Joseph Rubinfeld to Board of DirectorsRubinfeld expected to assist with FDA approval process for autologous cultured skin substitute, PermaDerm(TM)

27.08.2010 - Regenicin, Inc., a clinical-stage biotechnology company, announced that Dr. Joseph Rubinfeld, one of the four original founders of Amgen, Inc., has agreed to join the company's board of directors. Dr. Rubinfeld will be instrumental to assisting the compan's (…)

[Read article]

[Source: Bionity.com]

26.08.2010 | BioSpace: OncoMethylome Sciences S.A. Reports 2010 Half-Year Results and Announces New Strategy

DURHAM, NC, and LIEGE, BELGIUM - August 26, 2010 - OncoMethylome Sciences (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA), a leading molecular diagnostics company, announced today its 2010 half-year results and its new strategy. Highlights: Strategic/Commercial: Cervical (…)

[Read article]

[Source: BioSpace]

25.08.2010 | Business Wire: Research and Markets: Raising Disease State Awareness: Best Practices in Internal Brand Messaging for New Products | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/81e154/raising_disease_st) has announced the addition of the "Raising Disease State Awareness: Best Practices in Internal Brand Messaging for New Products" report to their offering. (…)

[Read article]

[Source: Business Wire]

01.01.1991 | NCBI PubMed: In vitro chromosome aberration assay of formulated recombinant human granulocyte-macrophage colony-stimulating factor in human peripheral blood lymphocytes.

The clastogenic potential of a recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) therapeutic protein formulation was assessed in human peripheral blood lymphocyte (HPBL) cultures. Final formulation, rather than pure protein, was evaluated to simulate (…)

[Read article]

[Source: NCBI PubMed]

19.08.2010 | NCBI PubMed: Duration of immunity induced by an equine influenza and tetanus combination vaccine formulation adjuvanted with ISCOM-Matrix.

Equine influenza is a contagious disease caused by equine influenza virus which belongs to the orthomyxovirus family. Outbreaks of equine influenza cause severe economic loses to the horse industry and consequently horses in competition are required to be regularly vaccinated (…)

[Read article]

[Source: NCBI PubMed]

19.08.2010 | NCBI PubMed: Ezetimibe Reduces Enlarged Prostate in an Animal Model of Benign Prostatic Hyperplasia.

PURPOSE: Benign prostatic hyperplasia is a common urinary tract disorder that affects aging men. The molecular mechanisms underlying benign prostatic hyperplasia are obscure and the development of animal models to test novel treatment strategies is challenging. We report that (…)

[Read article]

[Source: NCBI PubMed]

24.08.2010 | BioSpace: Winston K.C. Lam Joins Caris Life Sciences as Executive Vice President, Business Development and Chief Legal Officer

August 24, 2010 Caris Life Sciences(TM), Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest-quality anatomic pathology, molecular profiling, and blood-based diagnostic technologies, announced today that Winston K.C. (…)

[Read article]

[Source: BioSpace]

17.08.2010 | NCBI PubMed: Effect of Vitamin K-Dependent Protein Precursor Propeptide, Vitamin K Hydroquinone and Glutamate Substrate Binding on the {gamma}-Glutamyl Carboxylase's Structure and Function.

The gamma-glutamyl carboxylase utilizes four substrates to catalyze carboxylation of certain glutamic acid residues in vitamin K-dependent proteins. How the enzyme brings the substrates together to promote catalysis is an important question in understanding the structure and (…)

[Read article]

[Source: NCBI PubMed]

16.08.2010 | NCBI PubMed: IN VITRO AND IN VIVO EFFICACY OF FLORFENICOL FOR TREATMENT OF Francisella asiatica INFECTION IN TILAPIA.

Francisella asiatica is a recently described, Gram negative, facultative intracellular fish pathogen, known to be the causative agent of francisellosis in warmwater fish. Francisellosis outbreaks have increased in frequency amongst aquaculture commercial operations, and have (…)

[Read article]

[Source: NCBI PubMed]

17.08.2010 | Medical News Today: Pharmacy Associations Launch New Online Tool To Help Promote Medication Therapy Management (MTM) Practice

The American Pharmacists Association (APhA) and the Academy of Managed Care Pharmacy (AMCP) announced the launch of AMCP/APhA MTM ConnectionsTM - an online resource to advance the implementation of medication therapy management and other clinical services by pharmacists and (…)

[Read article]

[Source: Medical News Today]

17.08.2010 | Business Wire: KineMed s Study of Merck s Ezetimibe (ZETIA) Invited to Join Best of AHA Specialty Conference Poster Session | Business Wire

EMERYVILLE, Calif.-(BUSINESS WIRE)-The American Heart Association (AHA) has honored KineMed s abstract entitled œEzetimibe Treatment Stimulates Transport of Plasma Cholesterol into Fecal Neutral Sterols in Hyperlipidemic Humans  with a position in the Best of AHA Specialty (…)

[Read article]

[Source: Business Wire]

17.08.2010 | BioSpace: KineMed, Inc. s Study of Merck & Co., Inc. (MRK) s Ezetimibe (ZETIA(R) Invited to Join Best of American Heart Association Specialty Conference Poster Session

EMERYVILLE, Calif.-(BUSINESS WIRE)-The American Heart Association (AHA) has honored KineMed s abstract entitled œEzetimibe Treatment Stimulates Transport of Plasma Cholesterol into Fecal Neutral Sterols in Hyperlipidemic Humans  with a position in the Best of AHA Specialty (…)

[Read article]

[Source: BioSpace]

13.08.2010 | Business Wire: Maven Semantic: Database of International Allergy Research | Business Wire

DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Allergy research database. The system uses the context in which a given person appears, using artificial intelligence techniques to find out information not otherwise visible - for (…)

[Read article]

[Source: Business Wire]

12.08.2010 | Business Wire: Merck Announces Mandatory Conversion of its 6.00% Mandatory Convertible Preferred Stock | Business Wire

WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)-Merck & Co., Inc. today announced that, as of the close of business on August 13, 2010, the outstanding shares of the company s 6.00% Mandatory Convertible Preferred Stock (NYSE: MRK-PB) will mandatorily convert by their terms into a (…)

[Read article]

[Source: Business Wire]

01.02.1998 | NCBI PubMed: The three-dimensional solution structure of the SRC homology domain-2 of the growth factor receptor-bound protein-2.

A set of high-resolution three-dimensional solution structures of the Src homology region-2 (SH2) domain of the growth factor receptor-bound protein-2 was determined using heteronuclear NMR spectroscopy. The NMR data used in this study were collected on a stable monomeric (…)

[Read article]

[Source: NCBI PubMed]

11.08.2010 | Business Wire: Maven Semantic: Database of International Psoriasis Research Professionals | Business Wire

DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Psoriasis research database. , based on where they work, their job title, how many times they have published, where they have published, etc. The relevance can be fine tuned by the (…)

[Read article]

[Source: Business Wire]

11.08.2010 | Business Wire: Maven Semantic: Database of International Psoriasis Research Professionals | Business Wire

DUBLIN-(BUSINESS WIRE)-Maven Semantic (http:/www.mavensemantic.com) announces updates to their Psoriasis research database. , based on where they work, their job title, how many times they have published, where they have published, etc. The relevance can be fine tuned by the (…)

[Read article]

[Source: Business Wire]

01.08.2010 | NCBI PubMed: S-Adenosyl Methionine (SAMe) Augmentation in Major Depressive Disorder.

Am J Psychiatry. |-| Nelson JC. |-| The author has received lecture honoraria from Eli Lilly Global, Otsuka Asia, and Schering Plough/Merck (Asia); participated in industry-sponsored CME programs for AstraZeneca, Bristol-Myers Squibb, Forest, and Otsuka; served as a consultant (…)

[Read article]

[Source: NCBI PubMed]

09.08.2010 | Business Wire: Research and Markets: Examine Brazil's Pharmaceutical Market with This Essential and Comprehensive Report | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/045efe/the_pharmaceutical) has announced the addition of the "The Pharmaceutical Market: Brazil" report to their offering. These highly regarded world pharmaceutical market reports have (…)

[Read article]

[Source: Business Wire]

06.08.2010 | Business Wire: Phase Forward Announces United States Department of Justice Clearance | Business Wire

WALTHAM, Mass.-(BUSINESS WIRE)-Phase Forward Incorporated (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, announced that the United States Department of Justice has closed its investigation of the proposed acquisition of (…)

[Read article]

[Source: Business Wire]

05.08.2010 | BioSpace: Hana Biosciences, Inc. (HNAB) Appoints Robert Spiegel, M.D., FACP, to Board of Directors

SOUTH SAN FRANCISCO, Calif., Aug. 5, 2010 (GLOBE NEWSWIRE) - Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced the appointment of Robert (Bob) Spiegel, M.D., FACP, to the Company's Board of (…)

[Read article]

[Source: BioSpace]

04.08.2010 | Business Wire: In Pivotal Phase III Studies, Merck s Investigational Medicine Boceprevir Helped Majority of Patients with Chronic Hepatitis C Genotype 1 Infection Achieve Sustained Virologic Response, the Primary Endpoint of the Studies | Business Wire

WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)-Merck today reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic (…)

[Read article]

[Source: Business Wire]

04.08.2010 | BioSpace: In Pivotal Phase III Studies, Merck & Co., Inc. (MRK)'s Investigational Medicine Boceprevir Helped Majority of Patients with Chronic Hepatitis C Genotype 1 Infection Achieve Sustained Virologic Response, the Primary Endpoint of the Studies

WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)-Merck today reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic (…)

[Read article]

[Source: BioSpace]

30.07.2010 | Business Wire: Research and Markets: Medical Laboratories Industry in Argentina - Revealing Strategic Conclusions, Opportunities, Threats & Future Projections | Business Wire

DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/c22923/medical_laboratori) has announced the addition of the "Medical Laboratories Industry in Argentina" report to their offering. The following report shows a sectoral diagnosis which (…)

[Read article]

[Source: Business Wire]

30.07.2010 | Business Wire: Merck Announces Second-Quarter 2010 Financial Results | Business Wire

WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)-Merck & Co., Inc. (NYSE: MRK) today announced financial results for the second quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the second quarter of $0.86, which (…)

[Read article]

[Source: Business Wire]

01.04.2010 | NCBI PubMed: Guideline on the management of psoriasis in South Africa.

BACKGROUND; Psoriasis vulgaris is a chronic, relapsing, immune-mediated, potentially devastating disease, influenced by genetic and environmental factors, that can cause substantial morbidity and psychological stress and have a profound negative impact on patient quality of (…)

[Read article]

[Source: NCBI PubMed]

29.07.2010 | Marketwire: Unity Management Group Inc. Enters Into a Letter of Intent to Acquire Metropolitan Computing Corp. (MCC Legacy Products)

MIAMI, FL-(Marketwire - July 29, 2010) - Unity Management Group Inc. (PINKSHEETS: UYMG), a Health Resource Company specializing in Physician and Hospital Practice Management, Medical Discount Plans, Business Services, Billing Software and Technologies. Unity Management Group (…)

[Read article]

[Source: Marketwire]

01.08.2010 | NCBI PubMed: Pegylated interferon alpha 2b for treatment of ocular surface squamous neoplasia: a pilot study.

Purpose: To conduct a pilot study of pegylated interferon alpha 2b (PEGIFNalpha2b) for treatment of ocular surface squamous neoplasia (OSSN). Methods: Three patients with histologically proven OSSN were studied prospectively. Patients were given subconjunctival/perilesional (…)

[Read article]

[Source: NCBI PubMed]

30.03.2010 | NCBI PubMed: Antiproliferative Properties of Type I and Type II Interferon.

The clinical possibilities of interferon (IFN) became apparent with early studies demonstrating that it was capable of inhibiting tumor cells in culture and in vivo using animal models. IFN gained the distinction of being the first recombinant cytokine to be licensed in the USA (…)

[Read article]

[Source: NCBI PubMed]

27.07.2010 | Business Wire: Exact Sciences Obtains Exclusive License to OncoMethylome Sciences DNA Methylation Biomarkers | Business Wire

MADISON, Wis. & LIEGE, Belgium-(BUSINESS WIRE)-Exact Sciences Corp. (Nasdaq: EXAS) and OncoMethylome Sciences S.A. (Brussels: ONCOB) today announced that they have entered into a license agreement under which Exact Sciences has obtained exclusive, worldwide rights to up to (…)

[Read article]

[Source: Business Wire]

27.07.2010 | Business Wire: Merck Grants License to LabCorp for Development of Test To Potentially Identify Patients Likely to Respond to Hepatitis C Therapy | Business Wire

WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)-Merck today announced a non-exclusive license agreement with Laboratory Corporation of America Holdings (LabCorp) for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus (HCV) (…)

[Read article]

[Source: Business Wire]

27.07.2010 | Business Wire: Merck Announces Fourth-Quarter 2010 Dividend | Business Wire

WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)-At their meeting today, the Board of Directors of Merck & Co., Inc. declared a quarterly dividend of $0.38 per share on the company s common stock for the fourth quarter of 2010. Payment will be made on Oct. 7, 2010 to common (…)

[Read article]

[Source: Business Wire]

27.07.2010 | Business Wire: Sanofi-aventis and Merck Appoint Raul Kohan as CEO for the New Animal Health Joint Venture | Business Wire

PARIS & WHITEHOUSE STATION, N.J.-(BUSINESS WIRE)-Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Merck & Co., Inc. (NYSE: MRK) announced today that Raul E. Kohan will be appointed Chief Executive Officer of their proposed Animal Health joint venture. Sanofi-aventis and Merck (…)

[Read article]

[Source: Business Wire]

17.06.2010 | NCBI PubMed: Design, synthesis, and structure-activity relationship study of conformationally constrained analogs of indole-3-carboxamides as novel CB1 cannabinoid receptor agonists.

Novel tricyclic indole-3-carboxamides were synthesized as structurally restricted analogs of bicyclic indoles, and found to be potent CB1 cannabinoid receptor agonists. The CB1 agonist activity depended on the absolute configuration of the chiral center of the tricyclic ring. (…)

[Read article]

[Source: NCBI PubMed]